Risk factor
Resilient to price shocks
Profitability factor
Favourable analyst view
About
Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Target Price
The average target price of 000100.KS is 153842 and suggests 54% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
Buy
Sell